What does naltrexone cost for the Sinclair Method?
This article describes medications used for alcohol use disorder. It is educational and not medical advice. Talk to a licensed clinician about whether any specific medication fits your situation.
Three medications are FDA-approved to treat alcohol use disorder in the United States — naltrexone, acamprosate, and disulfiram (peer-reviewed overview) — and the Sinclair Method is built on the first of them. What the method costs has no single honest figure behind it: the cost is a parts list with four entries — a prescriber evaluation, a pharmacy fill, sometimes lab work, and follow-up support — each billed on its own logic, each moved by insurance status, pharmacy, and provider model. This page counts the parts, because a quoted total would be wrong for most readers by the time they read it.
The method, briefly
The Sinclair Method takes its name from J. David Sinclair, a researcher who co-authored early Finnish trials of "targeted" naltrexone — the medication taken before drinking, rather than every day with abstinence as a precondition (randomized trial, 2001). The mechanism is the whole idea. Naltrexone blocks opioid receptors, the part of the brain's reward wiring that appears to carry the pleasant lift a drink delivers — the blocking action the American Academy of Family Physicians describes for opioid-antagonist medications in alcohol dependence. Blunt that lift each time drinking happens, the reasoning goes, and over months the learned link between alcohol and reward fades; the method's proponents call this pharmacological extinction. The medication itself is FDA-indicated for the treatment of alcohol dependence; the targeted timing is a clinician-directed way of using it.
The other two approved medications do genuinely different jobs, which is why neither anchors a protocol like this. Acamprosate works on glutamate signaling — the brain's overworked "go" system — to help people who have already stopped drinking stay steadier, and disulfiram blocks the breakdown of acetaldehyde, a toxic byproduct of alcohol, so drinking while on it triggers a fast, unpleasant physical reaction (mechanism comparison). Only naltrexone's reward-blocking pairs naturally with an approach that begins while a person is still drinking.
The four line items
| Line item | What it covers | What moves it |
|---|---|---|
| Prescriber evaluation | A licensed clinician reviews health history, current medications, and goals; naltrexone is prescription-only | Live video vs. in-person vs. records review; how much follow-up is bundled in |
| Pharmacy fill | Oral naltrexone is a generic tablet; a long-acting injectable form also exists | Tablet vs. injectable; local vs. mail-order pharmacy; insurance coverage |
| Lab work | Some clinicians order liver-related blood tests before or during treatment | Whether labs are required, where they are drawn, and who bills for them |
| Follow-up and support | Side-effect check-ins, plan adjustments, coaching or behavioral support | What is included vs. charged per message, visit, or month |
Four details sit behind the table.
The evaluation is not a formality. Naltrexone's label makes it contraindicated for anyone taking opioid pain medication or currently dependent on opioids — it can blunt pain relief and can set off withdrawal in someone with opioids in their system — and pregnancy and liver problems are also on the review list. Screening for all of that is what the first visit is for.
The pharmacy line splits in two. The tablet is a generic, filled at an ordinary or mail-order pharmacy on whatever schedule the prescription sets. The injectable form is given by a healthcare provider about once a month — roughly twelve clinical encounters a year on that once-monthly basis — a different cost structure and different logistics from a bottle of tablets. The Sinclair Method as usually described is built around the tablet, since the whole point is timing the medication to drinking occasions.
Labs, when ordered, exist because naltrexone is processed by the liver; some clinicians want a baseline liver picture, and some re-check during treatment. Whether that cost is bundled is a direct question worth asking before entering payment details.
Follow-up is where the label and the marketing meet. The naltrexone label states the medication has not been shown to provide benefit except as part of an appropriate addiction-management plan, and the American Academy of Family Physicians recommends pairing any alcohol-use-disorder medication with behavioral support rather than a prescription alone. A service that includes structured follow-up is not padding the bill; it is matching how the medication was studied. The remaining unknowns are countable: platform fees, prescription-transfer fees, per-message charges, cancellation terms, refill policy.
For the cash-pay version of these questions — no insurance in the picture — see naltrexone without insurance.
The denominator behind the whole question
In 2024, 27.9 million people ages 12 and older in the United States had past-year alcohol use disorder — 9.7% of that age group, per NIAAA. About 2.1 million of them, 7.6%, received any alcohol-use treatment that year.
The number who received medication for alcohol use was smaller still: roughly 697,000, or 2.5% of people with past-year AUD.
Held against a fixed denominator: of every 100 people with past-year alcohol use disorder in 2024, about 8 received some form of treatment, and 2 or 3 received a medication of any kind — naltrexone, acamprosate, or disulfiram.
That 2.5% is easy to misread as a verdict on the medications. The better-supported reading is an access gap: most people with alcohol use disorder are never offered medication at all — the conversation simply never happens, because the person never sees a clinician who raises it or never reaches the point of asking.
The evidence grade underneath the method's medication is on record. AHRQ's 2023 systematic review of outpatient pharmacotherapy rated oral naltrexone and acamprosate as each carrying moderate-strength evidence for reducing return to drinking, while judging the evidence for disulfiram against placebo inadequate. That is the measured version of the claim: reviewed, graded, real — and still silent on any one person's case.
Clero was built to close that specific distance: it connects people with a licensed clinician by telehealth who can review whether naltrexone, including the targeted way the Sinclair Method uses it, fits a particular health history and goal.
What the count does not settle
Four line items and a treatment ladder answer the structural question, not the personal one. The numbers do not settle whether the goal is cutting down or stopping — the Sinclair Method is shaped around continued, targeted drinking, while acamprosate, by contrast, is approved for people who have already quit and want to stay stopped. They do not settle safety, where opioid use, pregnancy, and liver health each move the answer. And they do not settle whether a given provider's bundle matches a given person's situation, which is a comparison worth running across at least two providers before any payment details change hands.
Bottom line
Three approved medications; four separately billed parts; about 2 or 3 of every 100 people with alcohol use disorder in 2024 receiving any medication at all. What naltrexone costs on the Sinclair Method is not one number — it is a short list of countable parts, and every part can be priced with direct questions before committing to anything. For the protocol itself, see what the Sinclair Method is.
This article is general education, not medical advice or a price quote; medication decisions belong in a conversation with a licensed clinician who knows the full history. If stopping alcohol has ever brought on shaking, confusion, hallucinations, or a seizure, that is a 911 or emergency-room matter, not a scheduling question; for thoughts of self-harm, call or text 988; for confidential treatment referrals, SAMHSA's helpline is 1-800-662-4357 (1-800-662-HELP).
Want the private naltrexone update?
Join the launch list to hear first. Today, this is still educational content, not a prescription request or clinical intake.